EMYRIA LIMITED — Investor Presentation 2021

Sep 27, 2021

28/09/21

ASX Announcement

Emyria to present at Lifesciences webinar today

Emyria Limited (ASX: EMD) (Emyria or the Company), a data-backed treatment development and clinical services company, is pleased to announce that Dr., Michael Winlo, managing director for Emyria, will be presenting at the Proactive Lifesciences webinar.

A presentation will be delivered and is attached to this cover note.

Emyria will be one of three companies presenting, which also includes Amplia Therapeutics and Patrys.

Details of the event are as follows:

• Event: Proactive Lifesciences Webinar

• Webinar Presenter: Emyria’s Managing Director, Dr, Michael Winlo

• Date and Time: Tuesday 28th September 2021, 12pm Sydney time (AEST)

To register , please click on the link below:

https://event.webinarjam.com/register/91/gqy97hzy

For additional information, please contact: John Phillips at Proactive on john.phillips@proactiveinvestors.com or call 0431 597 771.

This announcement has been approved and authorised by the Managing Director of Emyria Limited.

For further information on Emyria :

Dr Michael Winlo Lexi O’Halloran Managing Director Media/Investor Relations 1300 436 363 + 61 (0) 404 577 076 mwinlo@emyria.com lexi@janemorganmanagement.com.au

Andrew Williams Media Relations +61 (0) 412 614 125 andreww@proflemedia.com.au

1

==> picture [137 x 40] intentionally omitted <==

About Emyria (www.emyria.com)

Emyria Limited is a data-backed, drug development company. Emyria’s Treatments target unmet needs and are focused on obtaining approval from major global regulators. Emyria’s drug development programs are informed by insights generated from extensive analysis of Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria’s independent clinical services ( Emerald Clinics - www.emeraldclinics.com.au)

Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.

Emyria’s first drug development program, EMD-003 is targeting unmet needs in mental health. Specifically psychological distress and the symptoms of anxiety, depression and stress.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

2

Emyria’s Unique Value Drivers

September 2021 | Dr Michael Winlo, MD & CEO

1

Contents

Emyria’s value drivers
(1) Attractive valuation	3
(2) Proprietary Real-World Evidence (RWE)	6
(3) Synthetic cannabinoid delivery platform	10
(4) MDMA analogue drug discovery pipeline	17
(5) National clinical service delivery	20
(6) An expert, global team	23
		2

(1) Attractive valuation

3

==> picture [720 x 59] intentionally omitted <==

Corporate snapshot

Key Metrics	Value	Emyria share price over 12 months	Emyria share price over 12 months
Shares on issue	254m
(Escrowed component)	100m
Last close ( 26 Sep 2021)	A$0.22
Market Capitalisation (17 Sep 2021)	A$56M
Cash (30 June 2021)	A$6.5m
Debt (30 June 2021)	-
Enterprise value	A~$49m
Total options (exercise price $0.114-0.45) expiring. 2022-24	62m	Source: https://emyria.com/for-investors/#Stock-Information

Top 20 = 60.48% Director ownership = 27.17%

==> picture [60 x 18] intentionally omitted <==

4

==> picture [720 x 59] intentionally omitted <==

Emyria (MC ~56m) is advancing in three, billion dollar verticals

Emyria has developed a clear strategy for value creation

1

FDA-, and TGA-approved cannabinoid medicines

FDA-approved MDMA2 analogue therapies

World-leading real-world 3 evidence

Emyria has developed a novel, ultra-pure cannabinoid dose form that meets all FDA requirements.

Pivotal registration trials are in planning for multiple target indications addressing major global unmet needs

Emyria has exclusive access to a library of unique MDMA-analogues with commercialisation potential as treatments for a range of neurological disorders and psychedelic-assisted therapies

Emyria has built a robust, proprietary, clinical-trial-grade evidence asset to assist with multiple FDA and TGA registration programs

==> picture [58 x 42] intentionally omitted <==

Market leaders

Acquired for US$7.2B (Feb 2021)

==> picture [122 x 42] intentionally omitted <==

Market cap: US$2.49B (Sep 21)

==> picture [127 x 38] intentionally omitted <==

Acquired for US$2.1B (Apr 2018)

==> picture [60 x 18] intentionally omitted <==

5

Sources: https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-completes-acquisition-gw-pharmaceuticals https://fnance.yahoo.com/quote/ATAI/ / https://www.roche.com/media/releases/med-cor-2018-04-06.htm

(2) Real-World Evidence

6

==> picture [720 x 59] intentionally omitted <==

Emyria’s Real-World Evidence (RWE) - 5,000 patients and counting

Our proprietary, robust and ethically-sourced clinical data:

2 - 98 years 56% 44 age range of patients female patients Unique primary indication s

* covers dose-response insights across a diverse set of patients

54% 53% 7.12 Patients presenting with symptoms of Patients presenting with symptoms Average concomitant medications moderate to severe anxiety of depression per patient at initial visit

* provides insights and IP which de-risks our drug development

programs

0-600 mg

Range of CBD prescribed doses are carefully titrated for each patient which gives Emyria unique dose response insights

0-197 mg

35%

Range of THC prescribed doses are carefully titrated for each patient Patients experiencing an adverse which gives Emyria unique dose event response insights

Data summary as of 01 DEC 2020

==> picture [60 x 18] intentionally omitted <==

7

==> picture [720 x 59] intentionally omitted <==

RWE now used in 75% of FDA approval applications, and growing

==> picture [89 x 15] intentionally omitted <==

==> picture [301 x 71] intentionally omitted <==

==> picture [463 x 51] intentionally omitted <==

==> picture [151 x 219] intentionally omitted <==

==> picture [60 x 18] intentionally omitted <==

8

Source: https://aetion.com/evidence-hub/infographic-what-role-does-rwe-play-in-fda-approvals/

==> picture [720 x 59] intentionally omitted <==

Curating RWE is a valuable business globally

Therapy area focus	Cancer	Eye disease + neurology	Diverse	40+ clinical indications
Care delivery	NO	NO	NO	YES
Novel drug development	NO	NO	NO	YES
				Direct input from patient
Data asset quality	Electronic Medical Records (needs cleaning)	Patient Registries (needs cleaning)	Insurance claims data (needs cleaning)	and clinicians (minimal cleaning,
				regulatory-grade)
	$475M	$209M	$227M	~$20M
Investment to date (AUD)
	Acquired: $2.9B Apr 18	Last funding: $152M Feb 20	Last funding: $110M May 21	Last funding: $5M Apr 21

==> picture [60 x 18] intentionally omitted <==

9

Source: https://www.crunchbase.com

(3) Synthetic (“pure”) cannabinoid delivery platform

10

==> picture [720 x 59] intentionally omitted <==

Medicinal cannabis is stuck at “2.0”; pharmaceuticals are “3.0” 40% of drugs behind the pharmacist's counter in the Western world are derived from plants that people have used for centuries. This includes the top 20 best selling prescription drugs in the United States today.

==> picture [687 x 251] intentionally omitted <==

----- Start of picture text -----

“1.0” “2.0” “3.0” Commercialisation
Medicine Natural origins First medical use Trials & registration Synthetic formulation status
1987 US$95bn lifetime
Pleurotus ostreatus 1970’s
Statins Synthetically sales of Lipitor
(oyster mushroom) First discovered
developed alone
US$750M USD for
Salix alba ~400 BC
Aspirin (white willow) First prepared as a tea 1899 “aspirin cardio” alone in 2020
Emyria’s novel
~8000 BCE synthetic delivery and Initial targets:
Cannabis sativa
Cannabis First medicinal use drug development mental health,
(cannabis)
documented programs target insomnia and pain
multiple indications
----- End of picture text -----

11

https://www.fiercepharma.com/pharma/from-old-behemoth-lipitor-to-new-king-humira-u-s-best-selling-drugs-over-25-years

==> picture [720 x 59] intentionally omitted <==

Unregistered botanical cannabinoids do not generate returns

There are 190 unregistered Cannabinoid products in Australia¹...

==> picture [386 x 174] intentionally omitted <==

$100m

Total Australian sales in 2020

1. https://freshleafanalytics.com.au/wp-content/uploads/2021/03/FreshLeaf-Analytics-H1-2021.pdf

==> picture [60 x 18] intentionally omitted <==

1. https://www.globenewswire.com/news-release/2021/02/16/2175953/0/en/GW-Pharmaceuticals-plc-ReportsFourth-Quarter-and-Year-End-2020-Financial-Results-and-Operational-Progress.html

...and only 1 registered product (Epidyolex by GW Pharma)

==> picture [89 x 82] intentionally omitted <==

$686m

Total Global sales in 2020² from rare paediatric epilepsy market only

03 Feb 21, GW acquired by Jazz Pharmaceuticals (USD$7.2B)

==> picture [48 x 50] intentionally omitted <==

Emyria has appointed Dr Karen Smith , Ex-Chief Medical Officer and Global Head of R&D at Jazz Pharmaceuticals to Chair Emyria’s Strategic Advisory (ASX Announcement 22 Feb 21)

12

==> picture [720 x 59] intentionally omitted <==

Botanical cannabinoids are in chronic oversupply

==> picture [376 x 219] intentionally omitted <==

==> picture [324 x 195] intentionally omitted <==

Source: Health Canada, MJBizDaily, a division of Anne Holland Ventures Inc. 2021

==> picture [60 x 18] intentionally omitted <==

13

==> picture [720 x 59] intentionally omitted <==

Emyria’s unique synthetic cannabinoid platform

==> picture [257 x 183] intentionally omitted <==

==> picture [96 x 54] intentionally omitted <==

Emyria is developing a novel cannabinoid delivery platform with leading North American contract drug manufacturer Altasciences (See ASX Announcement 13 August 2021)

Feature	Emyria’s Synthetic Platform	Emyria’s Synthetic Platform	Botanical alternatives
Safety	Synthetic CBD hasequivalentphysiological efects to botanical CBD [1]
			Botanical CBD can have high
	Synthetically manufactured		batch-to-batch variability
Reliability	cannabinoids ensure consistent batch-to-batch quality at scale		(see TGA audit results https://www.tga.gov.au/testing-medicinal- cannabis-products-being-supplied-sas-aus tralia)
	Consistent purity ensures		Plant-extracted cannabinoid
Regulatory	acceptability from all major		acceptable by some regulatory
	global regulators		agencies only
Cost	Far more cost efective over long-term		Currently expensive ($250-800/month for 150mg/day CBD)

==> picture [60 x 18] intentionally omitted <==

1. Maguire R, F, Wilkinson D, J, England T, J, O’Sullivan S, E: The Pharmacological Effects of Plant-Derived versus Synthetic Cannabidiol in Human Cell Lines. Med Cannabis Cannabinoids 2021. doi: 10.1159/000517120

14

==> picture [720 x 59] intentionally omitted <==

Emyria’s synthetic cannabinoid development strategy

An evidence based, synthetic (ultra-pure) cannabinoid product will create significant returns

• Regulators will continue to ensure pharmaceutical standards at federal level in US, Aus ( eg FDA statement, down scheduling of low dose CBD in Aus ) in line with historical precedents

• Botanical products currently non compliant (due to purity) or cost prohibitive (due to input costs)

• Demand for CBMP’s as substitute and adjunct therapeutics will rise based on safety and efficacy profile

• Big pharma will own API and supply chain when hurdles of safety, efficacy and scalable manufacture are met

==> picture [60 x 18] intentionally omitted <==

15

==> picture [720 x 59] intentionally omitted <==

Emyria’s growing cannabinoid patent portfolio

	Title	Ofcial No.	Status
	Use of Cannabidiol for the Treatment of Psychological Distress	2020904152	Provisional fled
	Use Of Cannabinoid for the Treatment of Psychological Distress	2021901086	Provisional fled
Emyria’s cannabinoid	Use Of Cannabidiol for the Treatment of Irritable Bowel Syndrome-Related	2021901672	Provisional fled
patents cover	Psychological Distress
unique formulations,	Use Of Cannabinoid Combination for the Treatment of Irritable Bowel	2021901674	Provisional fled
delivery	Syndrome-Related Psychological Distress
approaches and
“method of use”	Cannabidiol Dosing Regime	2021902001	Provisional fled
	Others in development covering unique delivery platforms, dose responses and clinical	Multiple provisionals expected 2021
	indications

==> picture [60 x 18] intentionally omitted <==

16

(4) MDMA analogue drug discovery and development

17

==> picture [720 x 59] intentionally omitted <==

Emyria’s MDMA analogues - a novel drug discovery pipeline

Emyria’s MDMA analogues

• Key features ● Exclusive access to >100 unique MDMA analogues ● >10 years of development at UWA

• Entire library exclusively optioned to Emyria

• Verified excellent purity and stability

• Early preclinical results for neurological disorders

• Potential for use as novel psychedelic-assisted therapeutics

• Accelerated 1. In-house expertise and partners to conduct development target-to-hit and hit-to-lead screening via program neuro-receptor analysis and validation studies 2. Lead compound selection informed by clinical, In partnership with pharmacological and medicinal chemistry experts

• 1. Multiple patent families filed to protect all distinct, drug classes identified

==> picture [60 x 18] intentionally omitted <==

18

==> picture [720 x 59] intentionally omitted <==

Psychedelic companies are attracting large valuations

Symbol	Company	Market Cap (AUD)
ATAI	ATAI Life Sciences N.V.	$3,216,535,666	Multiple psychedelics R+D targeting depression, anxiety, substance use,, TBI, Schizophrenia
CMPS	COMPASS Pathways Plc	$1,789,730,559	Testing synthesized psilocybin, administered with support from a trained therapist, to treat depression
GHRS	GH Research PLC	$1,464,094,233	(5-MeO-DMT) for depression
MNMD	Mind Medicine (MindMed) Inc.	$1,145,502,960	LSD experiential therapy for anxiety, 18-MC for substance abuse, LSD microdosing
CYBN:AQL	CYBIN INC.	$501,142,795	Psilocybin for MDD, deuterated tryptamine for anxiety and alcohol, phenethylamines
FTRP:CA	Field Trip Health Ltd.	$492,435,180	Ketamine-assisted psychotherapy clinical service
IHL:ASX	Inncannex Healthcare Ltd	$341,789,028	Commencing phase 2b trial for Psi-GAD psilocybin, targeting Generalised Anxiety Disorder
SEEL	Seelos Therapeutics Inc.	$272,158,453	Ketamine for major depressive disorder (MDD)
NUMI:CA	Numinus Wellness Inc.	$250,081,619	Ketamine clinics and clinical trials in MDMA-assisted therapy for PTSD & psilocybin for substance abuse
EMD:ASX	Emyria Limited	$55,900,000	Commencing phase IIb MDMA-assisted therapy trial for PTSD, Developing range of novel MDMA-analoguesfrom library of >100 compounds, real-world datageneration

==> picture [60 x 18] intentionally omitted <==

19

Source: https://psychedelicinvest.com/index/(accessed August 22nd)

(5) Clinical service delivery

20

==> picture [720 x 59] intentionally omitted <==

Caring for Australians, developing treatments for the globe

==> picture [181 x 122] intentionally omitted <==

Headquartered in Perth ,

Emyria operates a national clinical site network (Emerald Clinics) providing thousands of patients with unmet needs safe access to new and promising treatments while also generating robust and ethically-sourced clinical data .

==> picture [456 x 267] intentionally omitted <==

----- Start of picture text -----

Global registration targets
Northern Rivers Our data guides unique drug
Perth (HQ) development programs
Sydney targeting major unmet needs
and registration with the
Melbourne world’s largest regulators:
(USA), MHRA (UK), EMA (Europe)
----- End of picture text -----

==> picture [127 x 10] intentionally omitted <==

----- Start of picture text -----

Global registration targets
----- End of picture text -----

Our data guides unique drug development programs targeting major unmet needs and registration with the world’s largest regulators: FDA (USA), MHRA (UK), EMA (Europe)

==> picture [60 x 18] intentionally omitted <==

21

==> picture [662 x 211] intentionally omitted <==

----- Start of picture text -----

Emyria’s care model reduces opioid use by > 30%
190
Before care at
Emyria
Significant
142.5 High >90mg/day (>30%) reduction in
opioid use
The chart shows the oral morphine equivalent daily dose (“oMEDD”)
for a cohort of 220 patients presenting at Emyria’s Emerald Clinics Patients with 6+ months of
with a “HIGH” opioid consumption rating. cannabinoid usage
95
----- End of picture text -----

The chart shows the oral morphine equivalent daily dose (“oMEDD”) for a cohort of 220 patients presenting at Emyria’s Emerald Clinics with a “HIGH” opioid consumption rating. 95 oMEDD scores were derived by examining linked community

oMEDD scores were derived by examining linked community pharmacy dispensing data from NostraData/IQVIA in the 12 months prior and 12 months after starting care at Emerald Clinics.

Average oral morphine equivalent daily dose (oMEDD) trend (Pre vs Post Emyria) for a cohort of high opioid users and >6 months cannabinoid usage

47.5 The analysis reveals that these patients had a sustained and significant reduction in their daily oMEDD (more than 30%) made more compelling due to stability of their oMEDD scores in the 12 months leading up to treatment.

==> picture [585 x 29] intentionally omitted <==

----- Start of picture text -----

0
-12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12
----- End of picture text -----

==> picture [60 x 18] intentionally omitted <==

Months since first Emyria visit

22

23

==> picture [385 x 67] intentionally omitted <==

----- Start of picture text -----

6. Team of global experts
----- End of picture text -----

Board with deep clinical and commercial expertise

==> picture [701 x 353] intentionally omitted <==

----- Start of picture text -----

|||||
|---|---|---|---|
|Key Person|Role|Experience|Affiliations|
|Dr Stewart Washer|Cynata|(ASX:CYP) – stem cells|
|Chairman & Founder|Orthocell|(ASX:OCC) – regenerative medicine|
|Botanix|(ASX:BOT) – synthetic CBD|
|Dr Michael Winlo|Medical doctor|
|Managing Director|Director at|Linear Clinical Research|- Phase 1 clinical trials|
|Health Lead at|Palantir|(NYSE:PLTR) - Big Data analytics|
|MBA from|Stanford University|
|Dr Alistair Vickery|Specialist|general practitioner|
|Medical Director|Chair of|Black Swan Health|- mental health|
|Associate|Professor of Primary Health Care|
|Matt Callahan|Founder|Botanix|(ASX:BOT) - synthetic CBD|
|NED & Founder|Founder|Orthocell|(ASX:OCC) - regenerative medicine|
|4 products through|FDA approval|
|More than 20 years’|legal and IP experience|
|Professor Sir John|Knighted|in the UK for Services to Medicine|
|Tooke|Senior Independent Director,|BUPA Chile|
|Independent NED|Head of Medical Sciences,|University College London|
|Review board,|Google DeepMind|
|Immediate past|President Academy of Medical Sciences|

----- End of picture text -----

24

Emyria’s key advisors

Key	Person	Role	Experience	Afliations
		Dr Karen Smith, MD, PhD, MBA,	Multiple Directorshipswith innovative pharmaceutical companies
		LLM	Ex-Chief Medical OfcerandGlobal Head of R&DatJazz Pharmaceuticals
		Chair of Strategic Advisory	Overseen more than 100 clinical trials and20 regulatory approvals
		Assoc. Prof. Matthew Pigott, Dr,	Worked onantibiotic drug discoveryin collaboration withGlaxoSmithKline
		BSc PhD	Has spent the past 10 years developingMDMA analoguesfor Parkinson's disease and
		Medicinal Chemist, MDMA	otherneurological conditions
		Analogues
		Prof. Mathew Martin-Iverson, BSc	Head of Psychopharmacology, UWA
		Alta., PhD Br.Col.	Over35 yearsof experience studyingamphetaminesand otherpsychostimulants
		Neuropharmacologist

==> picture [60 x 18] intentionally omitted <==

25

Psychiatry leadership

Name	Role	Experience	Afliations
	Dr Eli Kotler, MBBS,	Medical DirectoratMalvern Private Hospital, specialising in drug & alcohol addiction
	MPM, FRANZCP,	recovery
	AFRACMA	Strongresearch background
	Principal Investigator	Board Member,Mind Medicine Australia
		Participant, inauguralCPAT course
	Dr Jeremy Tannenbaum,	Psychiatrist & Specialist Pain Medicine Physician trainee,Hollywood Private Hospital,
	MBBS(Hons), BSc, FRANZCP	The Anodyne Centre (holistic pain management clinic)&Fiona Stanley Hospital Completed medical elective withProf. David NuttatImperial College, London
	Consultant Psychiatrist
	Dr Richard	Director of Military Trauma Recovery Program, Salvado
	Magtengaard, MBBS,	Former Commissioned Ofcer within theRoyal Australian Navy
	BSc, RAN, RTD, FRANZCP	Member of Australasian Military Medical Association; afliations with the ADF Joint Health Command, St John's Ambulance and WAPOL
	Consultant Psychiatrist

==> picture [60 x 18] intentionally omitted <==

26

==> picture [720 x 59] intentionally omitted <==

Six reasons to invest in Emyria (ASX: EMD)

1

Attractive valuation

2 Proprietary RWE

Synthetic cannabinoid 3 delivery platform

Compared to industry vertical peers

Unique insights into what treatment is working and in whom, source of IP

Designed to meet FDA requirements, favourable COGS

4

MDMA-analogue drug discovery pipeline

National clinical service 5 delivery

6 Team of global experts

Multiple potential treatments for neurological and psychiatric conditions

Front-line experience treating patients with unmet needs

Over 24 FDA approvals, over 100 clinical trials, clinical and commercial experience

==> picture [60 x 18] intentionally omitted <==

27

28

==> picture [345 x 67] intentionally omitted <==

----- Start of picture text -----

For more information, please contact:
Dr. Michael Winlo, Managing Director
mwinlo@emyria.com
----- End of picture text -----